<DrugInformationSummary id="CDR0000817349"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Nivolumab and hyaluronidase-nvhy
         works by binding to and blocking  the protein PD-1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack the cancer cells. Hyaluronidase is a recombinant human form of an enzyme that breaks down a substance in the body called hyaluronic acid. This increases the absorption of drugs into tissue. Nivolumab and hyaluronidase-nvhy is a form of nivolumab that is given as an injection under the skin. This form can be given in less time than nivolumab, which is given through a vein. Nivolumab and hyaluronidase-nvhy is a type of immunotherapy drug called an immune checkpoint inhibitor.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab-and-hyaluronidase-nvhy">Nivolumab and Hyaluronidase-nvhy</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000817311">nivolumab and hyaluronidase-nvhy</TerminologyLink><GlossaryLink ref="CDR0000817319">nivolumab and hyaluronidase</GlossaryLink><USBrandNames><USBrandName>Opdivo Qvantig</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>nih-VOL-yoo-mab … HY-al-yoo-RAH-nih-days</TermPronunciation><MediaLink ref="CDR0000817827" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000817828" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f8c38fa-42f4-4387-9e8c-7a1c66855d8b&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Nivolumab and Hyaluronidase-nvhy</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f8c38fa-42f4-4387-9e8c-7a1c66855d8b&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_12"><Title>Use in Cancer</Title>                                                              
  <Para id="_13">Nivolumab and hyaluronidase-nvhy
         is approved to be used alone or with other drugs to treat adults with:</Para>                          
  <ItemizedList Style="bullet" id="_14">
   <ListItem><Strong><GlossaryTermRef href="CDR0000444983" dictionary="Cancer.gov" audience="Patient">colorectal cancer</GlossaryTermRef>.</Strong> Nivolumab and hyaluronidase-nvhy is used alone to treat <GlossaryTermRef href="CDR0000789683" dictionary="Cancer.gov" audience="Patient">microsatellite instability-high</GlossaryTermRef> (MSI-H) or <GlossaryTermRef href="CDR0000789741" dictionary="Cancer.gov" audience="Patient">mismatch repair deficient</GlossaryTermRef> (dMMR) cancer that has spread to other parts of the body and got worse after treatment with a <GlossaryTermRef href="CDR0000386207" dictionary="Cancer.gov" audience="Patient">fluoropyrimidine</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045465" dictionary="Cancer.gov" audience="Patient">oxaliplatin</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000635811" dictionary="Cancer.gov" audience="Patient">irinotecan hydrochloride</GlossaryTermRef>. It may be used after treatment with <GlossaryTermRef href="CDR0000767747" dictionary="Cancer.gov" audience="Patient">nivolumab</GlossaryTermRef> and <GlossaryTermRef href="CDR0000535555" dictionary="Cancer.gov" audience="Patient">ipilimumab</GlossaryTermRef>. </ListItem>
   <ListItem><Strong><GlossaryTermRef href="CDR0000444989" dictionary="Cancer.gov" audience="Patient">esophageal cancer</GlossaryTermRef></Strong> or <Strong><GlossaryTermRef href="CDR0000302458" dictionary="Cancer.gov" audience="Patient">gastroesophageal junction</GlossaryTermRef> cancer</Strong>. Nivolumab and hyaluronidase-nvhy is used:<ItemizedList Style="bullet" id="_15"><ListItem>for esophageal or gastroesophageal junction cancer that has been treated with a combination of chemotherapy and radiation therapy and then surgery to completely remove the cancer, but cancer cells were found in the removed tumor or <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef></ListItem><ListItem>for squamous cell carcinoma of the esophagus that cannot be removed by surgery or has spread or come back after treatment with a fluoropyrimidine and <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum</GlossaryTermRef>-based chemotherapy </ListItem><ListItem>for squamous cell carcinoma of the esophagus that cannot be removed by surgery or has spread to other parts of the body. It is given with a fluoropyrimidine and platinum-based chemotherapy as the first treatment</ListItem></ItemizedList></ListItem>
   <ListItem><Strong><GlossaryTermRef href="CDR0000454513" dictionary="Cancer.gov" audience="Patient">gastric (stomach) cancer</GlossaryTermRef></Strong>, <Strong>gastroesophageal junction cancer</Strong>, or <Strong>esophageal adenocarcinoma</Strong> that has spread. Nivolumab and hyaluronidase-nvhy is used with a fluoropyrimidine and platinum-based chemotherapy.¹</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046363" dictionary="Cancer.gov" audience="Patient">hepatocellular carcinoma</GlossaryTermRef></Strong> in patients whose cancer was treated with <GlossaryTermRef href="CDR0000509041" dictionary="Cancer.gov" audience="Patient">sorafenib tosylate</GlossaryTermRef> and after treatment with nivolumab and ipilimumab</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045135" dictionary="Cancer.gov" audience="Patient">melanoma</GlossaryTermRef>.</Strong> Nivolumab and hyaluronidase-nvhy is used:<ItemizedList Style="bullet" id="_16"><ListItem>for cancer that has spread or cannot be removed by surgery</ListItem><ListItem>for cancer that has spread or cannot be removed by surgery and has been treated with ipilimumab and nivolumab</ListItem><ListItem>as <GlossaryTermRef href="CDR0000045587" dictionary="Cancer.gov" audience="Patient">adjuvant therapy</GlossaryTermRef> in patients with one of the following stages of melanoma that has been completely removed by surgery: <GlossaryTermRef href="CDR0000045137" dictionary="Cancer.gov" audience="Patient">stage IIB</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045137" dictionary="Cancer.gov" audience="Patient">IIC</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045138" dictionary="Cancer.gov" audience="Patient">IIIA</GlossaryTermRef>, <GlossaryTermRef href="CDR0000793005" dictionary="Cancer.gov" audience="Patient">IIIB</GlossaryTermRef>, <GlossaryTermRef href="CDR0000793008" dictionary="Cancer.gov" audience="Patient">IIIC</GlossaryTermRef>, <GlossaryTermRef href="CDR0000793010" dictionary="Cancer.gov" audience="Patient">IIID</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000045139" dictionary="Cancer.gov" audience="Patient">IV melanoma</GlossaryTermRef></ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045323" dictionary="Cancer.gov" audience="Patient">non-small cell lung cancer</GlossaryTermRef>.</Strong> Nivolumab and hyaluronidase-nvhy is used:<ItemizedList Style="bullet" id="_17"><ListItem>with platinum-based chemotherapy before surgery for <GlossaryTermRef href="CDR0000561398" dictionary="Cancer.gov" audience="Patient">early-stage cancer</GlossaryTermRef></ListItem><ListItem>with platinum-based chemotherapy before surgery for early-stage cancer that does not have an abnormal <GeneName><GlossaryTermRef href="CDR0000796876" dictionary="Cancer.gov" audience="Patient">EGFR</GlossaryTermRef></GeneName> or <GeneName><GlossaryTermRef href="CDR0000721252" dictionary="Cancer.gov" audience="Patient">ALK</GlossaryTermRef></GeneName> gene and then alone after surgery</ListItem><ListItem>alone for cancer that has spread to other parts of the body and has gotten worse during or after treatment with platinum-based chemotherapy. Patients whose cancer has an abnormal <GeneName>EGFR</GeneName> or <GeneName>ALK</GeneName> gene should receive nivolumab and hyaluronidase-nvhy only if their cancer got worse after treatment with <GlossaryTermRef href="CDR0000454786" dictionary="Cancer.gov" audience="Patient">FDA</GlossaryTermRef>-approved therapy for these gene mutations.</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000661352" dictionary="Cancer.gov" audience="Patient">renal cell carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000444995" dictionary="Cancer.gov" audience="Patient">kidney cancer</GlossaryTermRef>) that is <GlossaryTermRef href="CDR0000478743" dictionary="Cancer.gov" audience="Patient">advanced</GlossaryTermRef>. Nivolumab and hyaluronidase-nvhy is used:<ItemizedList Style="bullet" id="_18"><ListItem>in patients who have already received <GlossaryTermRef href="CDR0000046739" dictionary="Cancer.gov" audience="Patient">angiogenesis inhibitor therapy</GlossaryTermRef></ListItem><ListItem>with <GlossaryTermRef href="CDR0000743915" dictionary="Cancer.gov" audience="Patient">cabozantinib-s-malate</GlossaryTermRef> as the first treatment</ListItem><ListItem>as the first treatment in some patients who have been treated with ipilimumab and nivolumab</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000597171" dictionary="Cancer.gov" audience="Patient">squamous cell carcinoma of the head and neck</GlossaryTermRef></Strong> that has spread to other parts of the body or has come back and got worse during or after treatment with platinum-based chemotherapy</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000783188" dictionary="Cancer.gov" audience="Patient">urothelial carcinoma</GlossaryTermRef></Strong> (a type of cancer in the bladder or <GlossaryTermRef href="CDR0000046095" dictionary="Cancer.gov" audience="Patient">urinary tract</GlossaryTermRef>). Nivolumab and hyaluronidase-nvhy is used:<ItemizedList Style="bullet" id="_19"><ListItem>	with <GlossaryTermRef href="CDR0000045230" dictionary="Cancer.gov" audience="Patient">cisplatin</GlossaryTermRef> and <GlossaryTermRef href="CDR0000508951" dictionary="Cancer.gov" audience="Patient">gemcitabine hydrochloride</GlossaryTermRef> as the first treatment for cancer that cannot be removed by surgery or has spread to other parts of the body</ListItem><ListItem>after surgery to remove cancer that has a high risk of coming back</ListItem><ListItem>for cancer that has spread and was treated with platinum-based chemotherapy, but it did not work, is no longer working, or the cancer has gotten worse</ListItem></ItemizedList></ListItem></ItemizedList>
  <Para id="_11">¹This use is approved under FDA’s <ExternalRef xref="https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm">Accelerated Approval Program</ExternalRef>. As a condition of approval, <GlossaryTermRef href="CDR0000799146" dictionary="Cancer.gov" audience="Patient">confirmatory trial(s)</GlossaryTermRef> must show that nivolumab and hyaluronidase-nvhy provides a clinical benefit in these patients.</Para><Para id="_20">For information about nivolumab that may apply to nivolumab and hyaluronidase-nvhy, see the Drug Information Summary for <DrugRef href="CDR0000767749" url="/about-cancer/treatment/drugs/nivolumab">Nivolumab</DrugRef>.</Para><Para id="_21">Nivolumab and hyaluronidase-nvhy
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Nivolumab and Hyaluronidase-nvhy</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/817311">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.33">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a625029.html">Nivolumab and Hyaluronidase-nvhy</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.34"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.35">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-opdivo-injection">FDA Approves Injectable Nivolumab, an Alternative to IV Infusion</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C212985">Find Clinical Trials for Nivolumab And Hyaluronidase-nvhy</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2025-03-13</DateFirstPublished><DateLastModified>2025-04-11</DateLastModified></DrugInformationSummary>
